PIK3CA and neoplasm: As the MEK inhibitor PD 0325901 appeared promising as a single agent but showed toxicity in clinical trials, and tumour growth inhibition was modest with the PI3K inhibitor GDC-0941 even at high doses, these and other PI3K and MEK inhibitors are now being investigated clinically in combination studies [8].